Trial Profile

A Phase 2a, Open-label, Exploratory Study to Evaluate Preliminary Efficacy of Subcutaneous MBX 1416 in Patients With Postbariatric Hypoglycemia (The STEADI Study)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 07 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Imapextide (Primary)
Indications Hypoglycaemia
Focus Therapeutic Use
Acronyms The STEADI Study
Sponsors MBX Biosciences

Most Recent Events

02 Jul 2026 Status changed from recruiting to completed.
11 May 2026 According to a MBX Biosciences media release, the results from this trial will be discussed at the Company's Obesity Day presentation today at 10:30 a.m. ET.
11 May 2026 Results presented in the MBX Biosciences Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com